Viewing data from:

PLERIXAFOR

ANDA

PLERIXAFOR | A205182 | DR REDDYS LABORATORIES LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: MOZOBIL(TE code: AP)

Medicare Part D Spending

CMS annual spending data for Plerixafor (2023)

Total Spending

$663K

Total Claims

Beneficiaries

Avg Cost/Unit

$2749.72

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain7 active DMFs1 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDPLERIXAFOR

DMF 264442012

HETERO LABS LTDPLERIXAFOR

DMF 266032012

BIOPHORE INDIA PHARMACEUTICALS PVT LTDPLERIXAFOR

DMF 295072015

MSN LABORATORIES PRIVATE LTDPLERIXAFOR

DMF 308772016

GLAND PHARMA LTDPLERIXAFOR

DMF 315722017

MATRIX PHARMACORP PRIVATE LTDPLERIXAFOR USP

DMF 323412018

ALEMBIC PHARMACEUTICALS LTDPLERIXAFOR

DMF 362782021

FRESENIUS KABI ONCOLOGY LTDInactivePLERIXAFOR

DMF 326152018

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Sep 22, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 24MG/1.2ML (20MG/ML)

0 patents0 exclusivities▴

SOLUTION;SUBCUTANEOUS | Approved: Jul 24, 2023

No patent or exclusivity listings for this strength.